Abstract
HUMAN protein C is a vitamin K-dependent plasma glycoprotein that circulates as an inactive zymogen. At the endothelial ceil surface, thrombin in complex with the integral membrane protein thrombomodulRi converts protein C to its active form by specific cleavage of an activation peptide1–3. The activated form of protein C has potent anticoagulant activity as a feedback regulator of thrombin generation (reviewed in refs 4–6), and also has profibrinolytic7–10, anti-ischaemic11 and anti-inflammatory properties12. Protein C is effective in the treatment of model and human thrombotic diseases4,13–16 but, except when it has been used to treat genetic or acquired deficiencies and microvascular thrombosis, it is administered as the activated enzyme, which has a short biological half-life. We have altered two putative inhibitory acidic residues near the thrombin cleavage site, which results in a 30-fold increase in substrate utilization by α-thrombin. We combined these changes with a genetically altered glycoform to generate a zymogen protein C with a 60-fold increased cleavage rate by free α-thrombin, independent of its cofactor thrombomodulin. We show that this 'preform' of protein C, unlike the natural circulating zymogen, can be activated by thrombin generated in clotting human plasma, resulting in an inhibition of further clot formation. Our data therefore show that we have engineered a site-activated agent, which only has anticoagulant activity when significant amounts of thrombin are being generated.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Esmon, N. L., Owen, W. G. & Esmon, C. T. J. biol. Chem. 257, 859–864 (1982).
Esmon, N. L., Prog. Hemost. Thromb. 9, 29–55 (1989).
Esmon, C. T. J. biol. Chem. 264, 4743–4746 (1989).
Esmon, C. T. Science 235, 1348–1352 (1987).
Gardner, J. E. & Griffin, J. H. Human Protein C and Thromboembolic Disease 265–278 (Grune and Stratton, New York, 1983).
Clouse, L. H. & Comp, P. C. New Engl. J. Med. 314, 1298–1304 (1986).
Comp, P. C. & Esmon, C. T. J. clin. Invest. 68, 1221–1228 (1981).
Zolton, R. P. & Seegers, W. H. Thromb. Res. 3, 23–27 (1973).
Romisch, J., Diehl, K.-H., Reiner, G. & Paques, E.-P. Fibrinolysis 5, 191–196 (1991).
Gruber, A., Marker, L. A., Hanson, S. R., Kelly, A. B. & Griffin, J. H. Circulation 84, 2454–2462 (1991).
Snow, T. R., Deal, M. T., Dickey, D. T. & Esmon, C. T. Circulation 84, 293–299 (1991).
Esmon, C. T., Taylor, F. B. & Snow, T. R. Thromb. Haemost. 66, 160–165 (1991).
Taylor, F. D. et al. J. clin. Invest. 79, 918–925 (1987).
Gruber, A., Griffin, J. H., Harker, L. A. & Hanson, S. R. Blood 73, 639–642 (1989).
Dreyfus, M. et al. New Engl. J. Med. 325, 1565–1568 (1991).
Okajima, K. et al. Am. J. Hemat. 33, 277–278 (1990).
Kisiel, W. J. clin. Invest. 64, 761–769 (1979).
Emerick, S. C. et al. in The Pharmacology and Toxicology of Proteins 351–367 (Liss, New York, 1987).
Chang, J.-Y. Eur. J. Biochem. 151, 271–224 (1985).
Feng, F. N., Meinwald, C., Vasquez, M. & Scheraga, H. A. Biochemistry 28, 3094–3105 (1989).
LeBonniec, B. F. & Esmon, C. T. Proc. natn. Acad. Sci. U.S.A. 88, 7371–7375 (1991).
LeBonniec, B. F., MacGillivray, R. T. A. & Esmon, C. T. J. biol. Chem. 266, 13796–13803 (1991).
Grinnell, B. W. et al. in Protein C and Related Anticoagulants (eds Bruley, D. & Drohan, W.) 13–46 (Gulf, Houston, 1990).
Ehrlich, H. J. et al. EMBO J. 9, 2367–2373 (1990).
Grinnell, B. W., Walls, J. D. & Gerlitz, B. J. biol. Chem. 226, 9778–9785 (1991).
Ye, J., Esmon, N. L., Esmon, C. T. & Johnson, A. E. J. biol. Chem. 266, 23016–23021 (1991).
Ehrlich, H. J., Jaskunas, S. R., Grinnell, B. W., Yan, S. B. & Bang, N. U. J. biol. Chem. 264, 14298–14304 (1989).
Gruber, A. & Griffin, J. H. Blood 79, 2340–2348 (1992).
Heeb, M. J., Bischoff, R., Courtney, M. & Griffin, J. H. J. biol. Chem. 265, 2365–2369 (1990).
Parkinson, J. F. et al. J. biol. Chem. 265, 12602–12610 (1990).
Grinnell, B. W., Berg, D. T., Walls, J. & Yan, S. B. Bio/Technology 5, 1189–1192 (1987).
Beckmann, R. J. et al. Nucleic Acids Res. 13, 5233–5247 (1985).
Devereux, J., Haeberli, P. & Smithies, O. Nucleic Acids Res. 12, 387–395 (1984).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Richardson, M., Gerlitz, B. & Grinnell, B. Enhancing protein C interaction with thrombin results in a clot-activated anticoagulant. Nature 360, 261–264 (1992). https://doi.org/10.1038/360261a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/360261a0
This article is cited by
-
Role of the activation peptide in the mechanism of protein C activation
Scientific Reports (2020)
-
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis
Nature Medicine (2007)
-
Recombinant human protein C, protein S and thrombomodulin as antithrombotics
Perspectives in Drug Discovery and Design (1994)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.